Mast Therapeutics (MSTX -40.2%) prices its public offering of 29,090,910 units at $0.275 per unit. Each unit consists of one share of common stock and one five-year warrant to purchase one share of common at $0.42. Net proceeds will be ~$7.3M. Closing date is February 16.
Net proceeds will fund the clinical development and commercialization of vepoloxamer, working capital and general corporate purposes.
Previously: Mast initiates equity offering (Feb. 9)
Subscribe for full text news in your inbox